|Articles|June 10, 2015
- Precision Medicine
- Volume 2
- Issue 1
Significance of the NCI Molecular Analysis for Therapy Choice Program
Author(s)Jonathan C. Trent, MD, PhD
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
Advertisement
Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
<<<
Articles in this issue
almost 11 years ago
Early Detection of Resistance in Lung Cancer Detected Through ctDNA in Urinealmost 11 years ago
Nivolumab and Future Biomarkers in NSCLCalmost 11 years ago
Screening Needed for Younger Breast Cancer Patients Based on Mutation Yieldalmost 11 years ago
Clinical Validation and Utility of a Liquid Biopsy in NSCLCalmost 11 years ago
Scoring System May Help Guide Therapy in Triple-Negative Breast CancerAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5